Converting Liver Cells into Insulin-producing Cells
Public on NASDAQ Mar, 2018
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Orgenesis is a vertically integrated biopharmaceutical company developing and manufacturing cell-therapy solutions. The company's MaSTherCell subsidiary is a global contract development and manufacturing organization. Through MaSTherCell, Orgenesis is able to deliver optimized process industrialization capacities to cell-therapy companies and speed up the arrival of these therapies onto the market.
MaSTherCell's customers include many pharmaceutical and biotechnology companies, as well as research institutions and hospitals involved in cell therapy.
Orgenesis is also developing its own proprietary cell therapies. Through its subsidiary, Orgenesis is developing solutions in the process of transdifferentiation (or cell reprogramming), whereby an adult cell is converted into another type of cell with a distinct phenotype and function. Orgenesis has utilized its proprietary technology and processes to successfully reprogram human liver cells into fully functional, glucose-responsive insulin-producing cells.
In June 2019, Orgenesis was granted an FDA orphan drug designation for its autologous insulin-producing cells.